You just read:

Janssen Announces U.S. FDA Breakthrough Therapy Designation Granted for Niraparib for the Treatment of Metastatic Castration-Resistant Prostate Cancer

News provided by

Janssen Pharmaceutical Companies of Johnson & Johnson

Oct 03, 2019, 16:17 ET